JZP 386

Drug Profile

JZP 386

Alternative Names: C-10323; Deuterated sodium oxybate - Concert Pharmaceuticals/Jazz Pharmaceuticals; Deuterium modified sodium oxybate - Concert Pharmaceuticals/Jazz Pharmaceuticals; JZP386; Sodium oxybate deuterated - Concert Pharmaceuticals/Jazz Pharmaceuticals

Latest Information Update: 20 Apr 2016

Price : $50

At a glance

  • Originator Concert Pharmaceuticals
  • Developer Concert Pharmaceuticals; Jazz Pharmaceuticals plc
  • Class Hydroxybutyrates; Organic deuterium compounds; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Narcolepsy

Most Recent Events

  • 30 Sep 2014 Concert Pharmaceuticals completes enrolment in its phase I trial for Narcolepsy (In volunteers) in United Kingdom before September 2014 (NCT02215499,
  • 21 Jul 2014 Phase-I clinical trials in Narcolepsy (In volunteers) in United Kingdom (PO)
  • 31 Jan 2014 European regulatory authorities approve Investigational Medicinal Product Dossier for JZP 386 in Narcolepsy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top